ADAPTIVE BIOTECH ($ADPT) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.20 per share, beating estimates of -$0.30 by $0.10. The company also reported revenue of $52,440,000, beating estimates of $43,532,141 by $8,907,859.
You can see Quiver Quantitative's $ADPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ADAPTIVE BIOTECH Insider Trading Activity
ADAPTIVE BIOTECH insiders have traded $ADPT stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:
- CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 8 sales selling 975,124 shares for an estimated $7,996,870.
- HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 3 sales selling 98,354 shares for an estimated $690,501.
- JULIE RUBINSTEIN (President and COO) has made 0 purchases and 2 sales selling 59,505 shares for an estimated $415,539.
- ROBERT HERSHBERG sold 53,000 shares for an estimated $402,270
- MICHELLE RENEE GRIFFIN has made 0 purchases and 2 sales selling 51,955 shares for an estimated $385,304.
- SHARON BENZENO (Chief Commercial Ofc Imm Med) has made 0 purchases and 2 sales selling 44,665 shares for an estimated $311,792.
- SUSAN BOBULSKY (Chief Commercial Officer, MRD) sold 26,023 shares for an estimated $181,640
- FRANCIS LO (Chief People Officer) has made 0 purchases and 2 sales selling 20,875 shares for an estimated $145,845.
- KYLE PISKEL (Chief Financial Officer) has made 0 purchases and 4 sales selling 10,568 shares for an estimated $73,307.
- PETER M NEUPERT sold 10,000 shares for an estimated $70,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ADAPTIVE BIOTECH Hedge Fund Activity
We have seen 117 institutional investors add shares of ADAPTIVE BIOTECH stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 3,107,939 shares (-33.1%) from their portfolio in Q4 2024, for an estimated $18,632,094
- VOYA INVESTMENT MANAGEMENT LLC added 2,389,674 shares (+6121.7%) to their portfolio in Q4 2024, for an estimated $14,326,095
- ARK INVESTMENT MANAGEMENT LLC removed 2,177,060 shares (-18.8%) from their portfolio in Q4 2024, for an estimated $13,051,474
- SOLEUS CAPITAL MANAGEMENT, L.P. added 1,870,393 shares (+168.1%) to their portfolio in Q4 2024, for an estimated $11,213,006
- PICTET ASSET MANAGEMENT HOLDING SA removed 1,274,846 shares (-97.9%) from their portfolio in Q4 2024, for an estimated $7,642,701
- NIKKO ASSET MANAGEMENT AMERICAS, INC. removed 900,747 shares (-11.6%) from their portfolio in Q4 2024, for an estimated $5,399,978
- SUMITOMO MITSUI TRUST GROUP, INC. removed 747,447 shares (-10.9%) from their portfolio in Q1 2025, for an estimated $5,553,531
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ADAPTIVE BIOTECH Government Contracts
We have seen $520,620 of award payments to $ADPT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPTIVE BIOTECHNOLOGIES CORPORATION:1186779 [24-013767]: $234,900
- CLONOSEQ TESTING FOR BOSTON AND WEST HAVEN VA HCS: $95,000
- ADAPTIVE IMMUNOSEQUENCING SERVICE: $76,200
- SARS-COV-2 IMMUNOSEQUENCING TESTING SERVICES: $61,150
- IMMUNO SEQUENCING SERVICE: $22,280
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ADAPTIVE BIOTECH Analyst Ratings
Wall Street analysts have issued reports on $ADPT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/18/2024
To track analyst ratings and price targets for ADAPTIVE BIOTECH, check out Quiver Quantitative's $ADPT forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
